The Management of Decompensated Heart Failure Resulting in Hospitalization: Proceedings from an Expert Meeting To Review Current Concepts and To Define Future DirectionsTezosentan in patients with acute heart failure and acute coronary syndromes: Design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4)☆,☆☆,★
Section snippets
Design and methods, end points, statistical considerations
RITZ-4 was a multicenter, randomized, double-blind, placebo-controlled trial, sponsored by Actelion, that investigated the use of tezosentan versus placebo in patients with acute heart failure in the setting of ACS. Patients were randomized in a 1:1 fashion to receive tezosentan or placebo for at least 24 and up to 48 hours. Patients randomized to the tezosentan group received 25 mg/h intravenously for 1 hour followed by 50 mg/h for 23 and up to 48 hours of treatment. The primary efficacy end
References (13)
- et al.
A novel biochemical approach to congestive heart failure: cardiac troponin T
Am Heart J
(1999) - et al.
Cardiac troponins in congestive heart failure
Am Heart J
(1999) - et al.
Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure
Am J Cardiol
(1999) - et al.
The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1
Int J Cardiol
(2000) - et al.
Tezosentan in patients with acute heart failure and acute coronary syndrome: design of the Randomized Intravenous Tezosentan Study (RITZ-4)
Am Heart J
(2002) - et al.
Monitoring of cardiac troponin I in patients with acute heart failure
Ann Clin Biochem
(1999)
There are more references available in the full text version of this article.
Cited by (11)
Cardiorenal syndrome: Misgivings about treatment options, clarity on prognosis
2015, Journal of Cardiac FailureEndothelin receptor antagonists
2006, Pharmacology and TherapeuticsEndothelin: 30 years from discovery to therapy
2019, HypertensionManagement of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation
2017, Journal of Thoracic DiseaseProfile of past and current clinical trials involving endothelin receptor antagonists: The novel "-sentan" class of drug
2006, Experimental Biology and MedicineEndothelin-1: The Yin and Yang on vascular function
2006, Current Medicinal Chemistry
- ☆
Reprint requests: Christopher M. O'Connor, MD, Duke Clinical Research Institute, 2400 N Pratt St, 0311 Terrace Level, Durham, NC 27705.
- ☆☆
E-mail: [email protected]
- ★
0002-8703/2003/$30.00 + 0
Copyright © 2003 Published by Mosby, Inc.